Emerging evidence on the pathobiology of mucositis

On behalf of The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)

Research output: Contribution to journalReview articlepeer-review

105 Citations (Scopus)


Background: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. Methods: Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011. Results: Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology. Conclusion: The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.

Original languageEnglish
Pages (from-to)3233-3241
Number of pages9
JournalSupportive Care in Cancer
Issue number11
Early online date11 Jul 2013
Publication statusPublished - Nov 2013
Externally publishedYes


  • Alimentary tract
  • Cancer therapy
  • Mucosal injury
  • Pharmacogenetics
  • Targeted drugs
  • Toxicity


Dive into the research topics of 'Emerging evidence on the pathobiology of mucositis'. Together they form a unique fingerprint.

Cite this